Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
Trial record 1 of 28 for:    ranibizumab delivery
Previous Study | Return to List | Next Study

Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Participants With Subfoveal Neovascular Age-Related Macular Degeneration (LADDER)

This study is currently recruiting participants. (see Contacts and Locations)
Verified October 2016 by Genentech, Inc.
Sponsor:
Information provided by (Responsible Party):
Genentech, Inc.
ClinicalTrials.gov Identifier:
NCT02510794
First received: July 17, 2015
Last updated: October 3, 2016
Last verified: October 2016
  Purpose
This is a Phase II clinical study to evaluate the efficacy, safety and pharmacokinetics of three different formulations of ranibizumab delivered via the Ranibizumab Port Delivery System (RPDS) implant compared with the standard of care (SOC) intravitreal (ITV) injections of ranibizumab, in participants with subfoveal neovascular age-related macular degeneration (AMD).

Condition Intervention Phase
Macular Degeneration
Drug: Ranibizumab ITV injection
Drug: Ranibizumab through RPDS Implant
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase II Multicenter, Randomized, Active Treatment-Controlled Study of The Efficacy and Safety of The Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients With Subfoveal Neovascular Age-Related Macular Degeneration

Resource links provided by NLM:


Further study details as provided by Genentech, Inc.:

Primary Outcome Measures:
  • Time Until a Participant First Requires the RPDS Implant Refill According to Protocol-Defined Refill Criteria [ Time Frame: Up to 31 months ]

Secondary Outcome Measures:
  • Percentage of Participants with AEs of Special Interest [ Time Frame: Up to 31 months ]
  • Mean Change in BCVA [ Time Frame: Baseline, at Month 9 ]
  • Mean Average Change in BCVA [ Time Frame: Baseline to up to Month 9 ]
  • Mean Change From Baseline in Central Foveal Thickness (CFT) Over Time as Assessed on Spectral Domain-Optical Coherence Tomography (SD-OCT) [ Time Frame: Baseline, up to 31 months ]
  • Percentage of Participants with Ocular and Non-Ocular Adverse Events (AEs) and Serious AEs (SAEs) [ Time Frame: Up to 31 months ]

Estimated Enrollment: 220
Study Start Date: September 2015
Estimated Study Completion Date: May 2018
Estimated Primary Completion Date: October 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: RPDS Group 1
Group 1 will receive ranibizumab delivered through the implant using formulation 1 according to protocol-defined refill criteria.
Drug: Ranibizumab through RPDS Implant
Ranibizumab delivered through the implant with three different formulations
Experimental: RPDS Group 2
Group 2 will receive ranibizumab delivered through the implant using formulation 2 according to protocol-defined refill criteria.
Drug: Ranibizumab through RPDS Implant
Ranibizumab delivered through the implant with three different formulations
Experimental: RPDS Group 3
Group 3 will receive ranibizumab delivered through the implant using formulation 3 according to protocol-defined refill criteria.
Drug: Ranibizumab through RPDS Implant
Ranibizumab delivered through the implant with three different formulations
Active Comparator: Ranibizumab 0.5 mg ITV injection
Participants in this arm will receive ranibizumab 0.5 milligrams (mg) monthly ITV injections of 10 mg/mL formulation.
Drug: Ranibizumab ITV injection
0.5-mg monthly ITV injections of 10-mg/mL formulation
Other Name: Lucentis®

  Eligibility

Ages Eligible for Study:   50 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age over 50 years
  • Newly diagnosed with wet AMD within 6 months of screening visit
  • Participant must have received at least 2 prior anti-VEGF injections. The most recent anti-VEGF injection must have been ranibizumab and must have occurred at least 7 days prior to the screening visit
  • Participant may have received up to 6 ITV anti-Vascular Endothelial Growth factor (VEGF) injections prior to the screening visit
  • Demonstrated response to prior SOC ITV anti-VEGF treatment
  • Best Corrected Visual Acuity (BCVA) using Early Treatment Diabetic Retinopathy Study (ETDRS) charts of 20/25-20/200 Snellen equivalent at the screening visit
  • Willingness and ability to provide signed informed consent

Exclusion Criteria:

  • Treatment with ITV anti-VEGF agents other than ranibizumab within 1 month prior to the randomization visit in either eye
  • Study eye treatment with ITV anti-VEGF agents other than ranibizumab within 1 month prior to the randomization visit
  • History of laser photocoagulation, Visudyne®, ITV corticosteroid injection, vitrectomy surgery, submacular surgery, device implantation, or other surgical intervention for AMD in the study eye
  • Prior participation in a clinical trial involving anti-angiogenic drugs, other than ranibizumab, in either eye within 2 months of the randomization visit
  • Subretinal hemorrhage in the study eye that involves the center of the fovea
  • Subfoveal fibrosis, or atrophy in the study eye
  • choroidal neovascularization (CNV) in either eye due to other causes, such as ocular histoplasmosis, trauma, or pathologic myopia
  • Uncontrolled ocular hypertension or glaucoma in the study eye
  • Uncontrolled blood pressure
  • Uncontrolled atrial fibrillation within 3 months of informed consent
  • History of myocardial infarction or stroke within the last 3 months prior to informed consent
  • History of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of ranibizumab or placement of the Implant, that might affect interpretation of the results of the study or renders the participant at high risk of treatment complications
  • Use of oral corticosteroids
  • Current treatment for any active systemic infection
  • Use of anticoagulants, anti-platelets (other than aspirin), or medications known to exert similar effects
  • Active malignancy within 12 months of randomization
  • History of allergy to fluorescein
  • Previous participation in any non-ocular (systemic) disease studies of investigational drugs within 1 month preceding the informed consent (excluding vitamins and minerals)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02510794

Contacts
Contact: Reference Study ID Number: GX28228 www.roche.com/about_roche/roche_worldwide.htm 888-662-6728 (U.S. and Canada) global.rochegenentechtrials@roche.com

  Show 52 Study Locations
Sponsors and Collaborators
Genentech, Inc.
Investigators
Study Director: Clinical Trials Hoffmann-La Roche
  More Information

Responsible Party: Genentech, Inc.
ClinicalTrials.gov Identifier: NCT02510794     History of Changes
Other Study ID Numbers: GX28228
Study First Received: July 17, 2015
Last Updated: October 3, 2016

Additional relevant MeSH terms:
Ranibizumab
Macular Degeneration
Wet Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases
Immunologic Factors
Physiological Effects of Drugs
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Growth Inhibitors
Antineoplastic Agents

ClinicalTrials.gov processed this record on April 21, 2017